Skip to main content
Erschienen in: Cancer Microenvironment 1/2015

01.04.2015 | Original Paper

Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer

verfasst von: Amanda F. Baker, Scott W. Malm, Ritu Pandey, Cindy Laughren, Haiyan Cui, Denise Roe, Setsuko K. Chambers

Erschienen in: Cancer Microenvironment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

A panel of nine hypoxia regulated genes, selected from a previously published fifty gene panel, was investigated for its ability to predict hypoxic ovarian cancer phenotypes. All nine genes including vascular endothelial growth factor A, glucose transporter 1, phosphoglycerate mutase 1, lactate dehydrogenase A, prolyl 4-hydroxylase, alpha-polypeptide 1, adrenomedullin, N-myc downstream regulated 1, aldolase A, and carbonic anhydrase 9 were upregulated in the HEY and OVCAR-3 human ovarian cell lines cultured in vitro under hypoxic compared to normoxic conditions as measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The gene panel was also elevated in HEY xenograft tumor tissue compared to HEY cells cultured in normoxia. The HEY xenograft tissue demonstrated heterogeneous positive immunohistochemical staining for the exogenous hypoxia biomarker pimonidazole, and the hypoxia regulated protein carbonic anhydrase IX. A quantitative nuclease protection assay (qNPA) was developed which included the nine hypoxia regulated genes. The qNPA assay provided similar results to those obtained using qRT-PCR for cultured cell lines. The qNPA assay was also evaluated using paraffin embedded fixed tissues including a set of five patient matched primary and metastatic serous cancers and four normal ovaries. In this small sample set the average gene expression was higher in primary and metastatic cancer tissue compared to normal ovaries for the majority of genes investigated. This study supports further evaluation by qNPA of this gene panel as an alternative or complimentary method to existing protein biomarkers to identify ovarian cancers with a hypoxic phenotype.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107(6):1053–1062CrossRefPubMed Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107(6):1053–1062CrossRefPubMed
2.
Zurück zum Zitat Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40CrossRefPubMed Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40CrossRefPubMed
3.
Zurück zum Zitat Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7(6):1661–1668PubMed Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7(6):1661–1668PubMed
4.
Zurück zum Zitat Hazelton DA, Hamilton TC (1999) Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1(1):59–63CrossRefPubMed Hazelton DA, Hamilton TC (1999) Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1(1):59–63CrossRefPubMed
5.
Zurück zum Zitat Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS (2010) Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16(21):5320–5328CrossRefPubMedCentralPubMed Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS (2010) Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16(21):5320–5328CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Bamias A, Pignata S, Pujade-Lauraine E (2012) Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 84(3):314–326CrossRefPubMed Bamias A, Pignata S, Pujade-Lauraine E (2012) Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 84(3):314–326CrossRefPubMed
7.
Zurück zum Zitat Khosravi-Shahi P, Cabezon-Gutierrez L (2012) Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer. Anticancer Agents Med Chem 12(8):982–987CrossRefPubMed Khosravi-Shahi P, Cabezon-Gutierrez L (2012) Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer. Anticancer Agents Med Chem 12(8):982–987CrossRefPubMed
8.
Zurück zum Zitat Betts GN, Eustace A, Patiar S, Valentine HR, Irlam J, Ramachandran A, Merve A, Homer JJ, Moller-Levet C, Buffa FM, Hall G, Miller CJ, Harris AL, West CM (2013) Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur J Cancer 49(1):156–165CrossRefPubMed Betts GN, Eustace A, Patiar S, Valentine HR, Irlam J, Ramachandran A, Merve A, Homer JJ, Moller-Levet C, Buffa FM, Hall G, Miller CJ, Harris AL, West CM (2013) Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur J Cancer 49(1):156–165CrossRefPubMed
9.
Zurück zum Zitat Williams E, Martin S, Moss R, Durrant L, Deen S (2012) Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch 461(1):33–39CrossRefPubMed Williams E, Martin S, Moss R, Durrant L, Deen S (2012) Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch 461(1):33–39CrossRefPubMed
10.
Zurück zum Zitat Milosevic M, Fyles A, Hedley D, Hill R (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14(3):249–258CrossRefPubMed Milosevic M, Fyles A, Hedley D, Hill R (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14(3):249–258CrossRefPubMed
12.
Zurück zum Zitat Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145CrossRefPubMed Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145CrossRefPubMed
13.
Zurück zum Zitat Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2):162–172PubMedCentralPubMed Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2):162–172PubMedCentralPubMed
14.
Zurück zum Zitat Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van d, V, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3(3):e47 Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van d, V, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3(3):e47
15.
Zurück zum Zitat Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428–435CrossRefPubMedCentralPubMed Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428–435CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM (2007) Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Investig 87(10):979–997CrossRefPubMed Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM (2007) Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Investig 87(10):979–997CrossRefPubMed
17.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408CrossRefPubMed Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408CrossRefPubMed
18.
Zurück zum Zitat Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145CrossRefPubMed Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145CrossRefPubMed
19.
Zurück zum Zitat Shin KH, Az-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC (2007) Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 6(1):70–75CrossRefPubMed Shin KH, Az-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC (2007) Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 6(1):70–75CrossRefPubMed
20.
Zurück zum Zitat Brahimi-Horn MC, Bellot G, Pouyssegur J (2011) Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21(1):67–72CrossRefPubMed Brahimi-Horn MC, Bellot G, Pouyssegur J (2011) Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21(1):67–72CrossRefPubMed
21.
Zurück zum Zitat Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, Chi JT (2010) Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6(9):e1001093CrossRefPubMedCentralPubMed Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, Chi JT (2010) Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6(9):e1001093CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol 789:203–209PubMed Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol 789:203–209PubMed
23.
Zurück zum Zitat de Saedeleer CJ, Copetti T, Porporato PE, Verrax J, Feron O, Sonveaux P (2012) Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells4. PLoS One 7(10):e46571CrossRefPubMedCentralPubMed de Saedeleer CJ, Copetti T, Porporato PE, Verrax J, Feron O, Sonveaux P (2012) Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells4. PLoS One 7(10):e46571CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, Rafii A (2011) Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One 6(12):e28561CrossRefPubMedCentralPubMed Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, Rafii A (2011) Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One 6(12):e28561CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Fong MY, McDunn J, Kakar SS (2011) Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6(5):e19963CrossRefPubMedCentralPubMed Fong MY, McDunn J, Kakar SS (2011) Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6(5):e19963CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Yu L, Deng L, Li J, Zhang Y, Hu L (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128(2):391–396CrossRefPubMed Yu L, Deng L, Li J, Zhang Y, Hu L (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128(2):391–396CrossRefPubMed
27.
Zurück zum Zitat Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A (2012) Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012:245756 Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A (2012) Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012:245756
28.
Zurück zum Zitat Kim K, Park WY, Kim JY, Sol MY, Shin DH, Park DY, Lee CH, Lee JH, Choi KU (2012) Prognostic relevance of the expression of CA IX, GLUT-1, and VEGF in ovarian epithelial cancers. Korean J Pathol 46(6):532–540CrossRefPubMedCentralPubMed Kim K, Park WY, Kim JY, Sol MY, Shin DH, Park DY, Lee CH, Lee JH, Choi KU (2012) Prognostic relevance of the expression of CA IX, GLUT-1, and VEGF in ovarian epithelial cancers. Korean J Pathol 46(6):532–540CrossRefPubMedCentralPubMed
29.
Zurück zum Zitat Cho H, Lee YS, Kim J, Chung JY, Kim JH (2013) Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Investig 31(9):607–615CrossRef Cho H, Lee YS, Kim J, Chung JY, Kim JH (2013) Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Investig 31(9):607–615CrossRef
30.
Zurück zum Zitat Airley R, Evans A, Mobasheri A, Hewitt SM (2010) Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 192(3):133–138CrossRefPubMed Airley R, Evans A, Mobasheri A, Hewitt SM (2010) Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 192(3):133–138CrossRefPubMed
31.
Zurück zum Zitat Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Li-Fehmi R (2011) Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 121(1):181–186CrossRefPubMed Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Li-Fehmi R (2011) Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 121(1):181–186CrossRefPubMed
32.
Zurück zum Zitat Hata K, Takebayashi Y, Akiba S, Fujiwaki R, Iida K, Nakayama K, Nakayama S, Fukumoto M, Miyazaki K (2000) Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 6(10):867–872CrossRefPubMed Hata K, Takebayashi Y, Akiba S, Fujiwaki R, Iida K, Nakayama K, Nakayama S, Fukumoto M, Miyazaki K (2000) Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 6(10):867–872CrossRefPubMed
33.
Zurück zum Zitat Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C (2012) Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo? 1. PLoS One 7(7):e40678CrossRefPubMedCentralPubMed Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C (2012) Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo? 1. PLoS One 7(7):e40678CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Frede S, Freitag P, Otto T, Heilmaier C, Fandrey J (2005) The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation 2. Cancer Res 65(11):4690–4697CrossRefPubMed Frede S, Freitag P, Otto T, Heilmaier C, Fandrey J (2005) The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation 2. Cancer Res 65(11):4690–4697CrossRefPubMed
35.
Zurück zum Zitat Lv XH, Chen JW, Zhao G, Feng ZZ, Yang DH, Sun WW, Fan JS, Zhu GH (2012) N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol 138(10):1703–1715CrossRefPubMed Lv XH, Chen JW, Zhao G, Feng ZZ, Yang DH, Sun WW, Fan JS, Zhu GH (2012) N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol 138(10):1703–1715CrossRefPubMed
36.
Zurück zum Zitat Wang B, Li J, Ye Z, Li Z, Wu X (2014) N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncol Rep 31(5):2279–2285PubMed Wang B, Li J, Ye Z, Li Z, Wu X (2014) N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncol Rep 31(5):2279–2285PubMed
37.
Zurück zum Zitat Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, Moch H, Tennstedt P (2011) Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459(2):193–200CrossRefPubMed Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, Moch H, Tennstedt P (2011) Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459(2):193–200CrossRefPubMed
38.
Zurück zum Zitat Hunakova L, Bodo J, Chovancova J, Sulikova G, Pastorekova S, Sedlak J (2007) Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 54(6):541–548PubMed Hunakova L, Bodo J, Chovancova J, Sulikova G, Pastorekova S, Sedlak J (2007) Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 54(6):541–548PubMed
39.
Zurück zum Zitat Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S (2006) Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49(6):594–602CrossRefPubMed Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S (2006) Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49(6):594–602CrossRefPubMed
Metadaten
Titel
Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer
verfasst von
Amanda F. Baker
Scott W. Malm
Ritu Pandey
Cindy Laughren
Haiyan Cui
Denise Roe
Setsuko K. Chambers
Publikationsdatum
01.04.2015
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1/2015
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-015-0166-x

Weitere Artikel der Ausgabe 1/2015

Cancer Microenvironment 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.